一圖讀懂康哲藥業(0867.HK)2022年全年業績
2022年,在疫情持續反覆、全球滯脹風險上升等多重複雜背景下,康哲藥業(0867.HK)受益於合規高效的開放式商業化平台,再次取得穩健業績:全年實現營收91.50億元,同比增長9.8%;若全按藥品銷售收入計算營收104.97億元,同比增長13.7%;實現淨利潤32.76億元,同比增長8.3%。
康哲藥業以商業化優勢挖掘未滿足需求,憑藉開放式創新孵化平台,已在全球佈局30款以FIC、BIC為主的創新管線,其中4款處於中國NDA審評中,3款將於年內獲批。康哲藥業圍繞專科領域縱深發展,已獨立運營皮膚醫美業務“康哲美麗”和眼科業務“康哲維盛”,並進入東南亞市場,持續拓寬業務廣度與深度,以適度多元且兼具規模效應的業務體系,護航集團持續健康發展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.